openPR Logo
Press release

Creative Diagnostics Introduces New Nipah Virus Antigens and Antibodies

04-26-2022 10:05 AM CET | Science & Education

Press release from: Creative Diagnostics

As a global leading supplier of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently launches a series of NiV recombinant antigen and antibody pairs. All of these new products are produced using standardized production processes to ensure the highest quality. Tests developed using these reagents can assist researchers in routine diagnostics and NiV vaccine development.

Nipah virus (NiV) was initially isolated and identified in 1999 during an outbreak of encephalitis and respiratory disease among pig farmers and close contacts of pigs in Malaysia and Singapore. It belongs to the newly created genus Henipavirus and is closely related to Hendra virus and Cedar virus. The Henipavirus family is pleomorphic, which means they come in a variety of shapes, typically 40 to 600 nm in diameter. The core of the virion contains a linear ribonucleoprotein (RNP) composed of negative-sense single-stranded RNA.

NiV is a highly pathogenic zoonotic virus carried by fruit bats (mainly Pteropus spp) and transmitted from bats to humans. Severe encephalitis and respiratory illnesses caused by NiV infection have occurred almost annually in Bangladesh and India since 2001. However, there are currently no licensed treatments and vaccines for NiV infection in humans.

NiV has two membrane-anchored glycoproteins involved in virion cell attachment and subsequent host cell entry, the attachment protein (G) and the fusion protein (F), which are ideal targets for neutralizing antibodies. Various immunization strategies have been developed to prevent NiV infection by utilizing G and/or F glycoprotein antigens, including viral vectors, subunit vaccines, virus-like particles (VLPs) and mRNA vaccines.

NiV causes acute encephalitis and high mortality (40-75%). Therefore, effective NiV vaccines and therapeutics are urgently needed. Laboratory detection of NiV can be performed using real-time polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA). Creative Diagnostics now expands its portfolio and releases a series of NiV recombinant antigen and antibody pairs for research use.

Antibodies products such as Anti-Nipah Virus G Protein monoclonal antibody (DMAB-A002), and Magic™ Anti-NIV gF Monoclonal antibody (CABT-RM237) are all available for sandwich ELISA. Recombinant Nipah Virus G Protein (DAGA-1004) and Recombinant Nipah Virus F Protein [His] (DAG-WT633) are also ready for research applications.

"Our NiV antigens are post-translationally modified and more closely resembling the native viral proteins, and these monoclonal antibodies can be used as a pair in sandwich ELISA with the rec. protein or in capture IgM assays. Our products are specific to NiV, no cross reaction with Dengue, Zika and Chikungunya envelope proteins." said Dr. Jessica Waldorf, chief scientific officer of R&D department of Creative Diagnostics.

If you want to know more details about NiV antigen and antibody products list or have any other questions about our research materials, please visit Creative Diagnostics at https://www.creative-diagnostics.com.

Creative Diagnostics
New York, USA

Contact Us

Tel: 1-631-624-4882 (USA)
44-161-818-6441 (Europe)
Fax: 1-631-938-8221
Email: info@creative-diagnostics.com

About Creative Diagnostics

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. It also provides contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. It aims to provide a trusted source for all researchers' assay development and manufacturing needs.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Creative Diagnostics Introduces New Nipah Virus Antigens and Antibodies here

News-ID: 2610389 • Views: 646

More Releases from Creative Diagnostics

Creative Diagnostics Launches Antibody-dependent Enhancement Assay Services
As a consulting and experimental service provider specializing in virology and microbiology, Creative Diagnostics recently introduces comprehensive services for antibody-dependent enhancement (ADE) assay. Flow cytometry, plaque assay or qPCR method are used to evaluate the ADE effect of test articles on virus infection in Fc receptor bearing cells. Antibody-dependent enhancement mainly refers to effects in the body caused by pathogen infection. In 1964, Hawkes and his team at the Australian National
Creative Diagnostics Launches Staphylococcal Enterotoxin Antigens
As a global leading supplier of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently launches a range of natural and recombinant staphylococcal enterotoxin antigens that are well validated in double-antibody sandwich enzyme-linked immunosorbent assay (ELISA). The newly introduced antigens consist of five of the most common staphylococcus aureus enterotoxins and are ideal for in vitro detection and diagnostic studies. Staphylococcus aureus is a Gram-positive spherical bacterium about 1
Creative Diagnostics Broadens Its Portfolio with New Pseudotyped GFP HPV
As a global leading supplier of of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently introduces new Pseudotyped GFP HPV for immunogenicity assessment in vaccine trials. This new series of HPV reporter virus particles can be used for measuring neutralizing anti-HPV antibodies in pseudovirion-based neutralization assays. Human papillomaviruses (HPVs) are double-stranded non-enveloped DNA viruses that infect keratinocytes of stratified squamous epithelia. Immunogenicity assessments in vaccine trials have focused
Creative Diagnostics Launches Fluorescently Labeled Gold Nanoparticles for Cellu …
With years of experience in the pharmaceutical and life science sector, Creative Diagnostics introduces a series of fluorescently labeled gold nanoparticles for efficient cell uptake, such as DiagNano™ Fluorophore Labeled Gold Nanoparticles, 10 nm, Cellular Uptake(GFL-10-CU), and DiagNano™ Fluorophore Labeled Gold Nanoparticles, 50 nm, Cellular Uptake (GFL-50-CU). These new products can be potentially used for cancer diagnostics, studies, and immunoassays. Colloidal and intracellular gold nanoparticles can be validated by confocal microscopy.

All 5 Releases


More Releases for NiV

Covid-19 Detection Kits Market Forecast 2026 | BGI, Abbott Laboratories, F. Hoff …
The global COVID-19 detection kits market is projected to foresee tremendous revenues over the coming years due to the rapidly increasing demand for highly accurate and efficient RT-PCR based COVID-19 detection kits. Additionally, the high risk of COVID-19 infection in geriatric population would drive the demand for COVID-19 detection kits further. According to a WHO situation report, the coronavirus infects individuals of all ages. However, up to date evidence suggests
Medical Non-invasive Ventilator (NIV) Market to Witness Huge Growth by 2026| Key …
ReportsnReports.com the exclusive leading provider of market research reports published research report on "Global Medical Non-invasive Ventilator (NIV) Market Research Report 2020". The Global Medical Non-invasive Ventilator (NIV) Market Report 2020 is a professional and in-depth study on the current state of the Medical Non-invasive Ventilator (NIV) Market. This report focuses on Medical Non-invasive Ventilator (NIV) volume and value at global level, regional level and company level. From a global perspective, this
Global 3D Printing Mask Market Size, Trends & Analysis - Forecasts To 2026
Global 3D Printing Mask Market Size, Trends & Analysis - Forecasts To 2026 By Component (Non-Invasive Ventilation mask, Filter, PEEP Valve), By Material (Alloy, Polymer, Ceramics, Biological Cell, Others), By End User (Hospitals, Medical Centers, Medical Institutes, Others), By Region (North America, Europe, Asia Pacific and Rest of the World); Vendor Landscape, End User Landscape and Company Market Share Analysis & Competitor Analysis 3D Printing Mask Market Insights The global 3D printing
Global Respiratory Care Devices Market In-Depth Research on Market Dynamics, App …
Global Respiratory Care Devices Market report lists and studies the leading competitors, also provides insights with strategic industry Analysis of the key factors influencing the market dynamics. With the study of competitor analysis, businesses get a knowhow of the strategies of key players in the market that includes but are not limited to new product launches, expansions, agreements, joint ventures, partnerships, and acquisitions. Global Respiratory Care Devices Market research report
Respiratory Protection Market Set to Grow with CAGR of 10.0% By 2026 With Leadin …
"Global Respiratory Protection Market 2020" and Upcoming Growth for 2027 from various Effect and factors about market environment, competitive landscape, historical and current data for forecast Growth with technological innovation, upcoming technologies and the technical progressive CAGR. Respiratory Protection is a professional and comprehensive report covering market parameters about the industry. The report pinpoints on the leading market competitors with explaining company profile depending on SWOT analysis to illustrate the
Respiratory Humidification Market for Invasive & Non-Invasive Ventilation - Indu …
Respiratory humidification is a method of artificial warming and humidifying of respiratory gas for mechanically ventilated patients. It is a method of artificially conditioning respiratory gas for the patient during therapy. Humidifiers are used in respiratory and acute care (RAC) and for the treatment of sleep apnea. Respiratory Humidification includes invasive ventilation, non-invasive ventilation, and HFNC, which all help humidify air delivered to patients with some form of severe respiratory